Novartis Canada Resumes Seasonal Influenza Vaccine Distribution as Health Canada Lifts Suspension

Novartis Canada Resumes Seasonal Influenza Vaccine Distribution as Health 
Canada Lifts Suspension 
Canadians urged to protect themselves for the coming flu season. 
Video: B-Roll - October 31, 2012: John Dorsey Head, Vaccines and Diagnostics 
at Novartis Pharmaceuticals Canada Inc. receiving Agriflu(®) influenza 
vaccine. Video available here. 
DORVAL, QC, Oct. 31, 2012 /CNW/ - Novartis Pharmaceuticals Canada Inc. has 
announced it is resuming distribution of two seasonal influenza vaccines in 
Canada, Fluad(®) and Agriflu(®), following the announcement by Health Canada 
earlier today that it has completed its review of safety information for 
Agriflu(®) and Fluad(®) and is releasing the two vaccines for immediate use. 
As a precautionary step, Health Canada had asked Novartis to suspend 
distribution of Agriflu(®) and Fluad(®) on October 26, 2012. 
Health Canada indicated it looked at the results of its own testing, conducted 
a health risk assessment, and reviewed information from its European partners 
as well as data submitted by Novartis in making its decision. None of the 
information reviewed by Health Canada indicated a safety issue. 
"This is good news for Canadians who can go with confidence to get their flu 
vaccination," said Dr. Allison McGeer, Microbiologist and Infectious Disease 
Consultant at Toronto's Mount Sinai Hospital. "Our job now as health care 
professionals is to make sure that anyvaccination programs that were 
interrupted get back on track as quickly as possible, so that Canadians are 
protected from influenza this season." 
Novartis anticipates no further interruption for those customers relying on 
Novartis vaccines. 
"We have remained confident in the safety and efficacy of our vaccines. We are 
pleased that Health Canada's assessment confirms this today and we can resume 
shipments to customers," said John Dorsey, Head, Vaccines and Diagnostics at 
Novartis Pharmaceuticals Canada Inc. "This resumption of supply will enable 
healthcare professionals to keep immunizing people against seasonal influenza." 
The Public Health Agency of Canada is now advising health care professionals 
in possession of these vaccines that they can start using them once again. The 
Public Health Agency of Canada closely monitors vaccination-related adverse 
events and, to date, it has received no reports of serious or unexpected 
adverse events related to these vaccines. The Public Health Agency of Canada 
and Health Canada will continue to work with Novartis to monitor the safety 
and effectiveness of the vaccines used here in Canada. Should a safety concern 
be identified immediate and appropriate action will be taken. 
"Patients' health and safety is our primary priority at Novartis which is why 
we took precautionary steps, although we were confident in the safety and 
efficacy of the Agriflu(®) and Fluad(®) vaccines," said Dr. Riad Sherif B., 
President of Novartis Pharmaceuticals Canada Inc. "We would like to thank 
Health Canada for itsprofessionalism, expertise and assessmentof our 
vaccines.We are pleased to have a rapid resolution of the situationin 
order that all Canadians can protect themselvesand their families.We 
believe it is critical that everyone gets their seasonal influenza vaccine 
this year." 
About Agriflu(®)
Agriflu(®) is an inactivated influenza subunit virus vaccine for immunization 
against influenza, indicated for everyone aged 6 months and older. Agriflu(®) 
is available in convenient, ready-to-use pre-filled syringes. It has been sold 
throughout Europe as Aggripal(®) since 1998. 
About Fluad(®)
Fluad(® )is an adjuvanted inactivated influenza subunit virus vaccine, 
specifically indicated in adults 65 years of age and older. Fluad(®) contains 
the adjuvant MF59(TM), which helps increase antibody production and improve 
immune response in the elderly. Fluad(®) is available in convenient, 
ready-to-use pre-filled syringes. It has more than 12 years of clinical 
experience and more than 60 million doses have been distributed worldwide. 
About Novartis Pharmaceuticals Canada Inc.
Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is 
committed to the discovery, development and marketing of innovative products 
to improve the well-being of all Canadians. In 2011, the company invested 
close to $100 million in research and development in Canada. Novartis 
Pharmaceuticals Canada Inc. employs more than 600 people in Canada. It was 
named for the seventh time as one of the "50 Best Employers in Canada" for 
2011. For further information, please consult www.novartis.ca. 
Andrea Gilpin, Ph.D, MBA Director, Corporate Communications Novartis 
Pharmaceuticals Canada Inc. Tel: (514) 631-6775 x 3356 
andrea.gilpin@novartis.com 
Image with caption: "John Dorsey Head, Vaccines and Diagnostics at Novartis 
Pharmaceuticals Canada Inc. receives Agriflu® influenza vaccine. (CNW 
Group/Novartis Pharmaceuticals Canada Inc.)". Image available at:  
http://photos.newswire.ca/images/download/20121031_C3872_PHOTO_EN_19973.jpg 
SOURCE: Novartis Pharmaceuticals Canada Inc. 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/October2012/31/c3872.html 
CO: Novartis Pharmaceuticals Canada Inc.
ST: Quebec
NI: MTC HEA HEA  
-0- Nov/01/2012 01:15 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.